Lucas Joost Van Pelt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lucas Joost Van Pelt has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Stephanie J. M. Middelkoop
University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Division of Nephrology, Groningen, NL-9700 RB, The Netherlands
4 shared publications - Coen A. Stegeman
Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
3 shared publications - Stephan J. L. Bakker
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 shared publications - André van der Ven
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications Anthony Ermens
Amphia Hospital, Breda, Netherlands
2 shared publications- Jan Cornelis ter Maaten
Department of Acute Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (11) , 2590-2601
Reagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays
Objectives: Fast estimations of direct oral anticoagulant (DOAC) plasma concentrations are useful in ruling out clinically significant concentrations before urgent surgical interventions. DOAC-specific anti-factor Xa (anti-Xa) assays are time consuming and not available 24/7 in most hospitals. Anti-Xa assays calibrated with low-molecular weight heparins (LMWHs) are widely available 24/7 and could give concentration estimations for anti-Xa DOACs (DXaIs). This study aimed to determine whether LMWH-calibrated anti-Xa assays could establish thresholds corresponding to DXaI concentrations associated with non-increased bleeding risk. Methods: Omniplasma was spiked with rivaroxaban, apixaban, or edoxaban in a 5–604 ng/mL range. One pooled patient sample was included per DXaI. Samples were analysed in 18 hospital laboratories, using 5 different analyser-reagent combinations (Stago Liquid anti-Xa on STA-R Max2/3, HemosIL Liquid anti-Xa on ACL-TOP350/550, Innovance Heparin on CS2500/CN3000, Biophen Heparin LRT on CS2500/CS5100, Roche anti-Xa on Cobas t511 analysers). Samples were analysed using local LMWH anti-Xa assay protocols using local reagent lots. Delta optical density and “LMWH” anti-Xa-activity were reported. DXaI concentrations were confirmed using liquid chromatography with tandem mass spectrometry detection. Results: Large differences in DXaI sensitivity between reagent groups were observed, which prevent formulation of universal threshold values for non-increased risk of bleeding. However, reagent-specific threshold values can be established with the exception of the Hyphen reagent group, due to high interlaboratory variability. Within analyser-reagent groups, a good correlation between spiked DXaI concentrations and “LMWH” activity assay readout is observed, permitting conversion between the two units up to 75 ng/mL for all DXaIs. Conclusions: Widely available rapid low-to-moderate DXaI concentration estimation can be achieved using LMWH-calibrated anti-Xa assays. Potential applications include ruling out clinically relevant DXaI concentrations before surgery and screening for the presence of a factor Xa inhibitor, but not specific DXaI monitoring.
- 22 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (11) , 2590-2601
Open AccessReagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays
Objectives: Fast estimations of direct oral anticoagulant (DOAC) plasma concentrations are useful in ruling out clinically significant concentrations before urgent surgical interventions. DOAC-specific anti-factor Xa (anti-Xa) assays are time consuming and not available 24/7 in most hospitals. Anti-Xa assays calibrated with low-molecular weight heparins (LMWHs) are widely available 24/7 and could give concentration estimations for anti-Xa DOACs (DXaIs). This study aimed to determine whether LMWH-calibrated anti-Xa assays could establish thresholds corresponding to DXaI concentrations associated with non-increased bleeding risk. Methods: Omniplasma was spiked with rivaroxaban, apixaban, or edoxaban in a 5–604 ng/mL range. One pooled patient sample was included per DXaI. Samples were analysed in 18 hospital laboratories, using 5 different analyser-reagent combinations (Stago Liquid anti-Xa on STA-R Max2/3, HemosIL Liquid anti-Xa on ACL-TOP350/550, Innovance Heparin on CS2500/CN3000, Biophen Heparin LRT on CS2500/CS5100, Roche anti-Xa on Cobas t511 analysers). Samples were analysed using local LMWH anti-Xa assay protocols using local reagent lots. Delta optical density and “LMWH” anti-Xa-activity were reported. DXaI concentrations were confirmed using liquid chromatography with tandem mass spectrometry detection. Results: Large differences in DXaI sensitivity between reagent groups were observed, which prevent formulation of universal threshold values for non-increased risk of bleeding. However, reagent-specific threshold values can be established with the exception of the Hyphen reagent group, due to high interlaboratory variability. Within analyser-reagent groups, a good correlation between spiked DXaI concentrations and “LMWH” activity assay readout is observed, permitting conversion between the two units up to 75 ng/mL for all DXaIs. Conclusions: Widely available rapid low-to-moderate DXaI concentration estimation can be achieved using LMWH-calibrated anti-Xa assays. Potential applications include ruling out clinically relevant DXaI concentrations before surgery and screening for the presence of a factor Xa inhibitor, but not specific DXaI monitoring.
- Open Access
- 17 November 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 162
Torque teno virus loads and leukocyte populations in stable outpatient solid organ transplant recipients
- 17 November 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 162
Open AccessTorque teno virus loads and leukocyte populations in stable outpatient solid organ transplant recipients
- Open Access
- 5 October 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 149, 107257
Plasma procalcitonin and urine interleukin-8, neutrophil gelatinase–associated lipocalin, and calprotectin in the diagnostic process of a urinary tract infection at the emergency department
- 5 October 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 149, 107257
Open AccessPlasma procalcitonin and urine interleukin-8, neutrophil gelatinase–associated lipocalin, and calprotectin in the diagnostic process of a urinary tract infection at the emergency department
- Open Access
- 16 August 2024
- Published by Taylor & Francis in Infectious Diseases
- Vol. 56 (12) , 1093-1101
Clinical usefulness of urine Gram stain for diagnosing urinary tract infections at the emergency department
BackgroundDiagnosis of urinary tract infections (UTIs) is a frequent challenge at the emergency department (ED). The clinical usefulness of the urine Gram stain (GS) is uncertain.ObjectiveWe studied the GS performance to clarify its clinical utility at the ED.MethodsUrine dipstick (UD), automated urinalysis (UF-1000i), GS and urine culture (UC) were performed in a cohort of consecutive adults presenting at the ED suspected of a UTI. GS performance was assessed and compared to UD and UF-1000i.ResultsA UTI diagnosis was established in 487/1358 (35.9%) episodes. Sensitivity and specificity for 'many' GS leucocytes was 33.7% and 95.4%; for 'many' GS bacteria 51.3% and 91.0%. GS diagnostic performance by ROC analysis was 0.796 for leucocytes and 0.823 for bacteria. GS bacteria performed better than UD nitrite comparable to UF-1000i bacteria. GS leucocytes underperformed compared to UD leucocyte esterase and UF-1000i leucocytes. UC was positive in 455 episodes. GS correctly predicted urine culture of gram-negative rods (PPV 84.6%). Prediction was poor for gram-positive bacteria (PPV 38.4% (cocci), 1.0% (rods)).ConclusionWith the exception of a moderate prediction of gram-negative bacteria in the UC, urine GS does not improve UTI diagnosis at the ED compared to other urine parameters.
- 16 August 2024
- Published by Taylor & Francis in Infectious Diseases
- Vol. 56 (12) , 1093-1101
Open AccessClinical usefulness of urine Gram stain for diagnosing urinary tract infections at the emergency department
BackgroundDiagnosis of urinary tract infections (UTIs) is a frequent challenge at the emergency department (ED). The clinical usefulness of the urine Gram stain (GS) is uncertain.ObjectiveWe studied the GS performance to clarify its clinical utility at the ED.MethodsUrine dipstick (UD), automated urinalysis (UF-1000i), GS and urine culture (UC) were performed in a cohort of consecutive adults presenting at the ED suspected of a UTI. GS performance was assessed and compared to UD and UF-1000i.ResultsA UTI diagnosis was established in 487/1358 (35.9%) episodes. Sensitivity and specificity for 'many' GS leucocytes was 33.7% and 95.4%; for 'many' GS bacteria 51.3% and 91.0%. GS diagnostic performance by ROC analysis was 0.796 for leucocytes and 0.823 for bacteria. GS bacteria performed better than UD nitrite comparable to UF-1000i bacteria. GS leucocytes underperformed compared to UD leucocyte esterase and UF-1000i leucocytes. UC was positive in 455 episodes. GS correctly predicted urine culture of gram-negative rods (PPV 84.6%). Prediction was poor for gram-positive bacteria (PPV 38.4% (cocci), 1.0% (rods)).ConclusionWith the exception of a moderate prediction of gram-negative bacteria in the UC, urine GS does not improve UTI diagnosis at the ED compared to other urine parameters.
- 15 January 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (2) , 219-220
Pleural Cryoglobulins
- 15 January 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (2) , 219-220
Pleural Cryoglobulins
- Open Access
- 1 May 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 87, 44-50
Influence of gender on the performance of urine dipstick and automated urinalysis in the diagnosis of urinary tract infections at the emergency department
- 1 May 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 87, 44-50
Open AccessInfluence of gender on the performance of urine dipstick and automated urinalysis in the diagnosis of urinary tract infections at the emergency department
- Open Access
- 26 November 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study
COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration, and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723–0.781) increasing to 0.875 (95% CI 0.806–0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.
- 26 November 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessA novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study
COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration, and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723–0.781) increasing to 0.875 (95% CI 0.806–0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.
- Open Access
A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study
COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.
Open AccessA novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study
COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.
- 1 August 2018
- Published by Elsevier in Thrombosis Research
- Vol. 168, 63-66
The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs
- 1 August 2018
- Published by Elsevier in Thrombosis Research
- Vol. 168, 63-66
The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs
- 1 August 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (8) , 1528-1534
Routine tests and automated urinalysis in patients with suspected urinary tract infection at the ED
- 1 August 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (8) , 1528-1534
Routine tests and automated urinalysis in patients with suspected urinary tract infection at the ED